Daily FNArena News - Small Caps

Tim Boreham, with some help from Ausbil, lines up his small-cap favourites from the August reporting season in Australia

Outlook for Universal Store Holdings remains resilient despite the impacts of covid lockdowns, with a number of analysts predicting the company will exceed its new store targets

After delivering a record year, growth remains in Maas Group’s line of sight, with the market anticipating both organic growth and acquisitions in the year ahead

Supply chain constraints have not hampered Data#3’s ability to deliver another record year, with the company describing constraint-driven backlog as a timing issue that will benefit FY23

Telix Pharmaceuticals’ prostate cancer imaging product Illucix is quickly conquering the USA, but management at the firm has (much) higher ambitions

A strong finish to the year looks to provide Corporate Travel Management with momentum as it moves into the new year, and should see the company benefit as markets reopen

Having delivered record sales in FY22, significant growth continues for Baby Bunting as the company pursues a bigger share of the domestic baby goods market through growth initiatives

FY22 results for Australian Clinical Labs missed expectations and brokers await an uptick in non-covid testing

Megaport’s FY22 result highlighted significant metrics disclosed for the first time, underpinning broker views of a solid longer term growth story

Dedicated lung imaging pioneer 4D medical sees itself as a software company, with lots of future potential, including from the US military